Not FDA-approved2Evidence: Smaller human trialsHormones

GHRP-21,2

Also called Pralmorelin, Growth hormone-releasing peptide 21

Key takeaway

GHRP-2 (growth hormone-releasing peptide 2) is a synthetic six-amino-acid peptide that FDA’s substance registry lists under the international name pralmorelin.1 In small human studies it raised growth hormone levels and appetite, and Japanese researchers have tested it as a diagnostic test for adult growth hormone deficiency.6,7 FDA has placed GHRP-2 in category 2 of its 503B compounding list, for substances that may present significant safety risks, citing possible immune reactions and reports of serious adverse events, though causality has not been established. Its 503A nominations list places GHRP-2 in category 3, nominated without adequate support.2,5 No FDA approval is reported in the sources reviewed here, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4

GHRP-2 at a glance

What it isA synthetic hexapeptide amide (D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2), also recorded as pralmorelin and KP-102, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, and its 503A nominations list, updated May 14, 2026, places it in category 3.2,5
Human evidenceA small randomized, placebo-controlled study of growth hormone and appetite, and a diagnostic study comparing people with and without growth hormone deficiency. FDA also reports serious adverse events in patients who received GHRP-2.2,6,7
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is GHRP-2?

GHRP-2 is a synthetic peptide of six amino acids, several of them in the unnatural D form, ending in an amide. FDA’s substance registry records it as pralmorelin, growth hormone-releasing peptide 2 and KP-102.1

FDA notes that GHRP-2 contains an unnatural amino acid, which makes the peptide harder to characterize.2

How is GHRP-2 thought to work?

Its registered name, growth hormone-releasing peptide 2, describes its intended action of prompting the release of growth hormone.1

The authors of a 2006 study describe it as a growth hormone secretagogue that acts like ghrelin, a hormone that stimulates appetite, and report that it raised both growth hormone levels and food intake.7

What do human studies show?

In a 2006 double-blind, randomized, placebo-controlled study, 19 healthy lean and obese adults ate more at a buffet meal after GHRP-2 than after placebo: about 10% more at the lower level tested and about 34% more at the higher. Growth hormone rose in all participants.7

In a 2007 Japanese study of 77 healthy people and 58 patients with severe growth hormone deficiency, peak growth hormone after GHRP-2 was far lower in the patients, and the authors proposed a cut-off for diagnosing the deficiency.6

FDA reports being aware of serious adverse events in patients who received GHRP-2, including a greater need for insulin to control blood sugar, deaths of critically ill study participants, infection and pancreatitis, though causality has not been established.2

These studies measured short-term hormone and appetite responses. The sources reviewed here do not show that GHRP-2 is effective or safe as a treatment for any condition.2,6,7

What the evidence base contains

  • Controlled human trial A double-blind, randomized, placebo-controlled study in 19 healthy lean and obese adults, each tested on three visits, published in 2006.7
  • Small, short, or incompletely reported human study A 2007 Japanese diagnostic study in 77 healthy people and 58 patients with severe growth hormone deficiency, measuring the growth hormone response to GHRP-2.6
  • Small, short, or incompletely reported human study Reports, cited by FDA, of serious adverse events in patients who received GHRP-2, including higher insulin needs, deaths of critically ill study participants, infection and pancreatitis, with causality not established.2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is GHRP-2 FDA-approved?

None of the sources reviewed here reports an approval of GHRP-2 by FDA.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.2

FDA’s list of bulk drug substances nominated for pharmacy compounding under section 503A, updated May 14, 2026, places GHRP-2 in category 3: substances nominated without adequate support.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.3,4

Timeline

  1. Results of a randomized, placebo-controlled study of GHRP-2 and appetite are published.7
  2. Results of a Japanese study of GHRP-2 as a diagnostic test for adult growth hormone deficiency are published.6
  3. FDA places GHRP-2 in category 2 under its 503B interim compounding policy, according to its safety-risk page.2
  4. FDA’s compounding safety-risk page, as last updated, keeps GHRP-2 in category 2.2
  5. FDA’s 503A nominations list, as last updated, places GHRP-2 in category 3.5

What is still unknown?

Whether it is effective for any condition: the human studies reviewed here measured short-term hormone and appetite responses or tested it as a diagnostic.6,7

Whether the serious adverse events FDA describes were caused by GHRP-2, which FDA states has not been established.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for GHRP-2: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for GHRP-2 are a bounded selection, not every registration or paper about GHRP-2. For the years before GHRP-2 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list GHRP-2 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name GHRP-2 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; on FDA’s compounding safety-risk list (category 2). Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of GHRP-2?

No FDA approval reported; on FDA’s compounding safety-risk list (category 2). Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
7
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats.↗Source date February 12, 2025
  2. Literature metadata · added November 15, 2026

    Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.↗Source date July 16, 2022
  3. Literature metadata · added November 15, 2026

    Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.↗Source date July 16, 2022

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to GHRP-2?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

21Selected dated records
28Connected citations
7Populated source years2008–2025
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

21 of 21 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 20Research Support, Non-U.S. Gov't 9Comparative Study 5Clinical Trial 2Clinical Trial, Phase I 1Controlled Clinical Trial 1Evaluation Study 1Letter 1Randomized Controlled Trial 1Research Support, U.S. Gov't, P.H.S. 1Review 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
21

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 21 dated records

Research hub

Explore the GHRP-2 evidence record

Open all 21 records →
21Dated records
1Evidence type
21Cited public sources
7Source years

Change ledger

Recently changed for GHRP-2

Open all 22 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Profile updated

GHRP-2 profile

We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Record added

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

PubMed lists PMID 10195374 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-02 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2018
Evidence lane
Literature metadata
Record added

Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.

PubMed lists PMID 15230633 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
October 25, 2018
Evidence lane
Literature metadata

Official-source collections

Source records for GHRP-2

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span January 23, 2008 to February 12, 2025. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 21

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats.↗

    PubMed lists PMID 16033952 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2005-07-20 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.↗

    PubMed lists PMID 35795807 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2022-06-06 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.↗

    PubMed lists PMID 9798733 in Endocrine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study.↗

    PubMed lists PMID 20045717 in Peptides as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-01-05 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure.↗

    PubMed lists PMID 27020037 in Endocrine journal as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2016-03-26 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.↗

    PubMed lists PMID 33197153 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2020-11-25 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry.↗

    PubMed lists PMID 20552695 in Rapid communications in mass spectrometry : RCM as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-07-30 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Identification and quantification of the doping agent GHRP-2 in seized unlabelled vials by NMR and MS: a case-report.↗

    PubMed lists PMID 24446112 in Drug testing and analysis as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-01-20 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism.↗

    PubMed lists PMID 18493103 in Endocrine journal as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-05-21 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves.↗

    PubMed lists PMID 8886623 in Endocrine journal as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1996-06 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells.↗

    PubMed lists PMID 9096259 in Life sciences as Comparative Study, Journal Article, with publication-date metadata of 1997 (year precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity.↗

    PubMed lists PMID 25761386 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2015-03-12 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Pralmorelin (GHRP-2) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  6. 6
    A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007) · PMID 17609397 ↗

    European Journal of Endocrinology · Official source · Source checked November 16, 2026

  7. 7
    Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake (2006) · PMID 16861611 ↗

    Obesity · Official source · Source checked November 16, 2026